Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study

Table 2 Clinicopathological characteristics of patients with combined hepatocellular cholangiocarcinoma

Item	Patients (n = 98)
Tumor number
Solitary	55 (56.1)
Multiple	39 (39.8)
NA	4 (4.1)
Tumor size, median [IQR]	4.5 [2.9, 6.5]
≤ 3cm (%)	26 (26.5)
3-5 cm (%)	36 (36.7)
> 5 cm (%)	34 (34.7)
NA	2 (2.0)
Resection margin (%)
≤ 1cm (%)	54 (55.1)
> 1cm (%)	21 (21.4)
NA	23 (23.5)
Macro VI (%)	24 (24.5)
Micro VI (%)	62 (63.3)
Lymph node metastasis (%)	12 (12.2)
TNM Stage (AJCC 8th) (%)
I	18 (18.4)
II	59 (60.2)
III	19 (19.4)
NA	2 (2.0)
Ki-67 (%)
≤ 50%	36 (55.4)
> 50%	29 (44.6)
CK7 (%)
Negative	9 (11.1)
Weak positive	29 (35.8)
Strong Positive	43 (53.1)
CK19 (%)
Negative	9 (10.8)
Weak positive	27 (32.5)
Strong Positive	47 (56.6)
HepPar-1 (%)
Negative	29 (34.1)
Weak positive	23 (27.1)
Strong Positive	33 (38.8)
GPC-3 (%)
Negative	16 (28.6)
Weak positive	13 (23.2)
Strong Positive	27 (48.2)
HCC differentiation (%)
Poorly differentiated	19 (41.3)
Well or moderate differentiated	27 (58.7)
ICC differentiation (%)
Poorly differentiated	30 (65.2)
Well or moderate differentiated	16 (34.8)
ICC percent (%)
≤ 50%	11 (30.7)
> 50%	16 (59.3)

Macro VI: Macrovascular invasion; Micro VI: Microvascular invasion; AJCC: American Joint Committee on Cancer; CK7: Cytokeratin 7; CK19: Cytokeratin 19; HepPar-1: Hepatocyte paraffin 1; GPC-3: Glypican-3; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; NA: Not available.